Spurred on by OrbiMed partner's diagnosis, Vanqua Bio takes aim at neurodegenerative disease with blue-chip backers

The FDA’s recent approval of Biogen’s Aduhelm has provided a spark plug for neuroscience research across the biopharma spectrum with investors more likely than ever to jump on board. A Chicago biotech now has its own clutch of blue-chip backers to pursue drugs across a range of indications — and it all started from a close colleague’s own diagnosis and search for a cure.